Stockhouse.com uses cookies on this site. By continuing to use our service, you agree to our use of cookies. Cookies are used to offer you a better browsing experience and to analyze our traffic. We also use them to share usage information with our partners. See full details.
I Agree
×
Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Privacy Policy | Disclaimer

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Privacy Policy | Disclaimer
Please Try Again {{ error }}

Send my password

Return to Login
SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

Breaking & Recent News Therapeutic Solutions International Inc TSOI

Therapeutic Solutions International, Inc. is focused on immune modulation for the treatment of several specific diseases. The Company is developing a range of immune-modulatory agents to target certain cancers, schizophrenia, suicidal ideation, and traumatic brain injury, and for daily health. The Company's flagship product, QuadraMune, is a multi-patented synergistic blend of pterostilbene... see more

Recent & Breaking News (OTCPK:TSOI)

San Diego Top Doctor Collaborates with Therapeutic Solutions International to Report QuadraMune(TM) Immune Boosting Data in Clinical Trial

PR Newswire June 1, 2020

San Diego "Top Doctor" James Veltmeyer Collaborates With Therapeutic Solutions International in Cord Blood Based Immunotherapy for COVID-19 Damaged Lungs

PR Newswire May 12, 2020

Therapeutic Solutions International Leverages Filed and Issued Intellectual Property to Develop COVID-19 Nutraceutical Candidate: QuadraMune(TM)

PR Newswire May 5, 2020

Therapeutic Solutions International Enters into Multi-Million Dollar Master Sales Agreement with Publicly Traded iBrands Corporation

PR Newswire January 21, 2020

Therapeutic Solutions International Reports Inhibition of Microglial Activation with NeuroStilbene

PR Newswire January 8, 2020

Therapeutic Solutions International Enters Into Multi-million Dollar Master Sales Agreement With WCTE, Inc.

PR Newswire December 23, 2019

Therapeutic Solutions International Signs Letter of Intent to License Adult Stem Cell Therapy for Treatment of Chronic Traumatic Encephalopathy to WCTE, Inc., a Wes Chandler Company

PR Newswire December 16, 2019

Therapeutic Solutions International Enters Into Multi-million Dollar Master Sales Agreement With Tiva Bio

PR Newswire December 12, 2019

Therapeutics Solutions International Signs Agreement With Beijing Regenesis Biotechnology to License and Develop Patent for Anti-aging Use of Cord Blood Plasma and NanoStilbene

PR Newswire November 11, 2019

Therapeutic Solutions International Reports Augmentation of Rejuvenating Activity of Cord Blood Plasma by Pterostilbene

PR Newswire November 4, 2019

Therapeutic Solutions International Reports NanoStilbene(TM) Protects the Immune System from Cancer Chemotherapy

GlobeNewswire September 9, 2019

Feng Lin, MD, Ph.D., Joins Therapeutic Solutions International as Chief Scientific Officer

GlobeNewswire September 3, 2019

Therapeutic Solutions International Inc. Reports Revenues Up 850% for Q2

GlobeNewswire August 29, 2019

Therapeutic Solutions International Announces Positive Clinical Data Using NanoStilbene(TM) to Stimulate Immune System in Advanced Cancer Patients

GlobeNewswire August 26, 2019

Therapeutic Solutions International Collaborates with Right to Try Foundation on Novel Means of Protecting Patients While Hyper-accelerating Drug Development

GlobeNewswire August 5, 2019

NanoStilbene(TM) Nutraceutical Shown to Increase Ability of Cyclophosphamide Chemotherapy to Suppress Cancer

GlobeNewswire July 29, 2019

Therapeutic Solutions International Reports its NanoStilbene(TM) Nutraceutical Product Enhances Efficacy of FDA Cleared Cancer Immunotherapy in Animal Model of Cancer

GlobeNewswire July 22, 2019

Therapeutic Solutions International adds Nano Cannabidiol to NanoMyros for Inhibition of Microvesicle and Exosome Release in Prostate Cancer

GlobeNewswire July 15, 2019

Therapeutic Solutions International Develops Adjuvant Technology to Enhance Prostate Cancer Suppressing Properties of NanoPSA

GlobeNewswire July 11, 2019

Therapeutic Solutions International Develops Glucoraphanin + NanoStilbene Encapsulated product for reduction of Prostate Specific Antigen (PSA)

GlobeNewswire July 8, 2019